Efficacy and safety of sirolimus (rapamycin) for thyroid eye disease: a systematic review
Keywords:
Graves Ophthalmopathy, Sirolimus, MTOR InhibitorsAbstract
This systematic review aimed to summarize available evidence on the efficacy and safety of sirolimus (rapamycin) in the treatment of thyroid eye disease (TED) in terms of improvements in clinical activity score and/or Gorman diplopia score, as well as the frequency and severity of adverse events. In total, two case reports, one case series, and three clinical trials involving 50 patients with moderate-to-severe TED with or without intractable diplopia who failed the first-line treatment of intravenous glucocorticoid and received either oral sirolimus or other immunosuppressants were included in the analysis. Sirolimus appears to be effective and safe in managing TED, as indicated by improvements in both clinical activity score and Gorman diplopia score, as well as satisfactory safety profile. However, further studies are warranted to fully elucidate its efficacy and safety.
References
1. Boulakh L, Nygaard B, Bek T, et al. Nationwide incidence of thyroid eye disease and cumulative incidence of strabismus and surgical interventions in Denmark. JAMA Ophthalmol 2022;140:667-73.
2. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Front Endocrinol 2020;11:615993.
3. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
4. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021;185:G43-67.
5. Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 2020;16:104-16.
6. Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 2022;11:e220189.
7. Lee ACH, Kahaly GJ. Novel approaches for immunosuppression in Graves' hyperthyroidism and associated orbitopathy. Eur Thyroid J 2020;9(Suppl 1):17-30.
8. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91.
9. National Institutes of Health. DailyMed - Rapamune- Sirolimus Solution rapamune- sirolimus tablet, Sugar Coated. U.S. National Library of Medicine. Accessed 25 June 2025. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc
10. Lee ACH, Kahaly GJ. Pathophysiology of thyroid-associated orbitopathy. Best Pract Res Clin Endocrinol Metab 2023;37:101620.
11. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
12. Chang S, Perry JD, Kosmorsky GS, Braun WE. Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy. Ophthalmic Plast Reconstr Surg 2007;23:225-6.
13. Roos JCP, Eglitis V, Murthy R. Inhibition of fibrotic contraction by sirolimus (rapamycin) in an ex vivo model of thyroid eye disease. Ophthalmic Plast Reconstr Surg 2021;37:366-71.
14. Zhang M, Chong KKL, Chen ZY, et al. Rapamycin improves Graves' orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight 2023;8:e160377.
15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
16. ROBINS-I V2 tool. Accessed 25 June 2025. Available from https://www.riskofbias.info/welcome/robins-i-v2
17. Lanzolla G, Maglionico MN, Comi S, et al. Sirolimus as a second-line treatment for Graves' orbitopathy. J Endocrinol Invest 2022;45:2171-80.
18. Comi S, Cosentino G, Lanzolla G, et al. Long-term outcome of Graves' orbitopathy following treatment with sirolimus. J Endocrinol Invest 2024;48:607-18.
19. Lai KKH, Wang Y, Pang CP, Chong KKL. Sirolimus versus mycophenolate mofetil for triple immunosuppression in thyroid eye disease patients with recent-onset intractable diplopia: a prospective comparative case series. Clin Exp Ophthalmol 2023;51:878-81.
20. Roos JCP, Murthy R. Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves' orbitopathy. Eye 2019;33:679-82.
21. Lee ACH, Kahaly GJ. Targeted immunotherapies for Graves' thyroidal & orbital diseases. Front Immunol 2025;16:1571427.
22. Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf 2019;42:813-25.
23. U.S. Food and Drug Administration. Rapamune (sirolimus) tablets label. Accessed 25 June 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021110s058lbl.pdf
24. Lee ACH, Riedl M, Frommer L, Diana T, Kahaly GJ. Systemic safety analysis of mycophenolate in Graves' orbitopathy. J Endocrinol Invest 2020;43:767-7.
25. Feng W, Hu Y, Zhang C, et al. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis. Bioengineered 2022;13:14719-29.
26. Nie T, Lamb YN. Correction: Teprotumumab: a review in thyroid eye disease. Drugs 2022;82:1757.
27. Ostrowski RA, Bussey MR, Shayesteh Y, Jay WM. Rituximab in the treatment of thyroid eye disease: a review. Neuroophthalmology 2015;39:109-15.
28. Euarte AF, Xavier NF, Sales Sanz M, Cruz AAV. Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg 2024;40:367-73.
29. Comi S, Cosentino G, Sabini E, et al. Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus. J Endocrinol Invest 2025;48.1677-82.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Hong Kong Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
